Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 3/20 | 0.55 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | F11 | P03951 | 1/20 | 0.55 |
| ▸ | KIF11 | P52732 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29456298 | 1.00 | AR (0.55) | ARCA12CA9F11KIF11 | |
| Acetic Acid SCHEMBL27456011 | 0.91 | CA12 (0.50) | ARCA12CA9F11KIF11 | |
| SCHEMBL20660889 | 0.87 | KIF11 (0.63) | ARCA12CA9F11KIF11 | |
| SCHEMBL30946289 | 0.87 | KIF11 (0.63) | ARCA12CA9F11KIF11 | |
| SCHEMBL4294313 | 0.86 | AR (0.50) | ARCA12CA9F11KIF11 | |
| SCHEMBL1082200 | 0.82 | KIF11 (0.56) | ARCA12CA9F11KIF11 | |
| SCHEMBL762006 | 0.81 | CA12 (0.59) | ARCA12CA9F11KIF11 | |
| Valeric Acid SCHEMBL27545189 | 0.81 | AR (0.43) | ARCA12CA9F11KIF11 | |
| SCHEMBL25904486 | 0.78 | KIF11 (0.43) | ARCA12CA9F11KIF11 | |
| SCHEMBL7896641 | 0.77 | KIF11 (0.50) | ARCA12CA9F11KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258354-B2 | AhR modulators | IDEAYA BIOSCIENCES, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240327354-A1 | GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS | INSTITUT PASTEUR DE LILLE (FR) | 2024-10-03 | — | — | US | disclosed |
| EP-3749669-B3 | AHR MODULATORS | IDEAYA BIOSCIENCES INC (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-111683950-B | AhR modulators | 伊迪亚生物科学有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2023-08-03 | — | — | US | disclosed |
| EP-4219495-A1 | AHR MODULATORS | Ideaya Biosciences, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4219495-A1 | AHR MODULATORS | Ideaya Biosciences, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3749669-B1 | AHR MODULATORS | IDEAYA BIOSCIENCES INC (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230039955-A1 | AhR MODULATORS | IDEAYA BIOSCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2014081697-A2 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140142114-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142114-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2014-05-22 | — | — | US | disclosed |
| US-8450363-B2 | Inhibitors of Jun N-terminal kinase | ELAN PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20130072494-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | ELAN PHARMACEUTICALS, INC. | 2013-03-21 | — | — | US | disclosed |
| EP-2393806-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | Elan Pharmaceuticals Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20100331335-A1 | Inhibitors of Jun N-Terminal Kinase | ELAN PHARMACETICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| WO-2010091310-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| EP-1474401-A2 | NOVEL ARYL- AND HETEROARYLPIPERAZINES | NOVO NORDISK A/S (DK) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003066604-A2 | NOVEL ARYL- AND HETEROARYLPIPERAZINES | NOVO NORDISK A/S (DK) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | HDAC1, HDAC2, HDAC3 | AR 1068/4885CA12 3462/4885CA9 4034/4885 |
| US-20240327354-A1 | GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, ATP4B | AR 4370/4885CA12 4622/4885CA9 2996/4885 |
| US-20230039955-A1 | AhR MODULATORS | AHR, ARNT, RORB | AR 80/4885CA12 4719/4885CA9 4689/4885 |
| US-12258354-B2 | AhR modulators | AHR, ARNT, RORB | AR 77/4885CA12 4726/4885CA9 4694/4885 |
| US-20130072494-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | AR 1510/4885CA12 4434/4885CA9 3495/4885 |
| US-20140142114-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | CYP3A5, ABCC5, CXXC5 | AR 3315/4885CA12 2469/4885CA9 965/4885 |
| US-20100331335-A1 | Inhibitors of Jun N-Terminal Kinase | CHUK, MAPK6, MAPK3 | AR 1510/4885CA12 4434/4885CA9 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.